NCT00246519View on ClinicalTrials.gov

Pharmacogenomic Evaluation of Antihypertensive Responses

PHASE4CompletedINTERVENTIONAL
Enrollment

1,701

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Hypertension
Interventions
DRUG

Hydrochlorothiazide

atenolol 50 or 100 mg hydrochlorothiazide 12.5 or 25 mg

DRUG

Atenolol

atenolol 50 mg, then 100 mg if BP \< 120/70, then add HCTZ 12.5 mg if BP \< 120/70, then HCTZ 25 mg if BP \< 120/70

Trial Locations (3)

30322

Emory University, Atlanta

32610

University of Florida Department of Community Health and Family Medicine, Gainesville

55905

Mayo Clinic, Rochester

All Listed Sponsors
lead

University of Florida

OTHER

NCT00246519 - Pharmacogenomic Evaluation of Antihypertensive Responses | Biotech Hunter | Biotech Hunter